Tran Ben, McKendrick Joe
Department of Medical Oncology, Box Hill Hospital, Victoria, Australia.
Can J Urol. 2010 Apr;17(2):5120-3.
Metastatic urachal cancer is a rare disease and subsequently, does not have a defined systemic treatment. Although urachal cancer is most commonly adenocarcinoma and histologically similar to colon cancer, treatment selection is usually based upon location (the proximity of the urachus to the bladder) with bladder cancer regimens the most commonly prescribed. We report a case of metastatic urachal cancer where the immunohistochemical profile's similarities to colon cancer led to treatment with colon cancer specific chemotherapy. Our case is the first to report urachal cancer treated with and responding to modified FOLFOX6. In the age of targeted therapy, where molecular biology drives treatment selection, our case highlights that in rare tumors, when evidence is often lacking, a common sense approach can often prevail.
转移性脐尿管癌是一种罕见疾病，因此尚无明确的全身治疗方案。尽管脐尿管癌最常见的是腺癌，组织学上与结肠癌相似，但治疗方案的选择通常基于肿瘤位置（脐尿管与膀胱的距离），最常采用的是膀胱癌治疗方案。我们报告了一例转移性脐尿管癌病例，其免疫组化特征与结肠癌相似，因此采用了结肠癌特异性化疗。我们的病例是首例报告采用改良FOLFOX6方案治疗并有效的脐尿管癌。在靶向治疗时代，分子生物学指导治疗方案的选择，我们的病例表明，在罕见肿瘤中，由于往往缺乏证据，常识性方法通常更为适用。
